Fully biologically active when compared to standard. The specific activity is determined by its binding ability in a functional ELISA. Immobilized rHuIL-36γ at 1μg/ml can bind recombinant human IL-1 Rrp2 Fc Chimera with a range of 0.15-5μg/ml.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered concentrated solution in PBS, pH7.4.
Endotoxin
Less than 1EU/μg of rHuIL-36γ, 169a.a. as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
Interleukin-36 (IL-36) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36γ is secreted when transfected into 293-T cells and it could constitute part of an independent signaling system analogous to interleukin-1 alpha (IL-1A), beta (IL-1B) receptor agonist and interleukin-1 receptor type I (IL-1R1). Furthermore, IL-36γ also can function as an agonist of NF-kappa B activation through the orphan IL-1-receptor-related protein 2. Recombinant human IL-36γ is synthesized as a 19kDa, 169 amino acid (a.a.) protein that contains no signal sequence, no prosegment and no potential N-linked glycosylation site. Human to mouse, IL-36γ shares 53%a.a. identity. Within the family, IL-36γ shares about 25%~55%a.a. sequence identity with IL-1RA, IL-1β, IL-36RA, IL-36α, IL-37, IL-36β and IL-1F10.